InVEST44: The Go-to Panel for Early Identification of Off-Target Interactions
Our InVEST44 panel is specifically designed for the early identification of off-target interactions in drug discovery. This comprehensive panel includes 44 well-validated molecular targets, such as G-protein-coupled receptors (GPCRs), ion channels, enzymes, transporters, and nuclear receptors—crucial components in both core systems (central nervous, cardiovascular, respiratory) and secondary organs (gastrointestinal, renal).
The InVEST44 panel covers the industry standard set of targets for detecting potential adverse effects early in the drug development process, ensuring a safer, more efficient path from discovery to clinical trials. Backed by the Reaction Biology commitment to high quality data, our InVEST44 panel will help you identify safety risks associated with off-target activities before they become a costly issue.
Ideal for the early identification of off-target interactions
Targets 44 critical molecular sites, including GPCRs, ion channels, enzymes, transporters, and nuclear receptors
Comprehensive coverage of core and secondary organs and systems
Minimizes risk of adverse effects in drug development
Optimize your drug development process today with the InVEST44™ panel and ensure the safety of your compounds from the earliest stages.
Related resources
In Vitro Safety Pharmacology Profiling
Screen your compounds against a broad range of targets that may cause adverse drug reactions in humans including receptors, transporters, enzymes, and ion channels.
Determining a dosing schedule and route of administration for in vivo efficacy testing. Gain insights into whether your drug act on its target in vivo.
